Why Is LNTH Stock Up After Hours?
Synopsis
Lantheus said that the FDA approved its PYLARIFY TruVu injection.
Shares of Lantheus Holdings, Inc. (LNTH) rose 5% after hours on Friday after the company announced that the U.S. Food and Drug Administration has approved its PYLARIFY TruVu injection.
The injection is indicated for imaging certain lesions in men with prostate cancer.
It is now expected to be commercially available in the fourth quarter of 2026.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.